+61 2 8296 0000 [email protected]
About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian life sciences, health and medical technologies company (originated as VRI Biomedical Ltd in 2000) with a focus on immune health and immunotherapeutic products.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, Lactobacillus fermentum PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne’s focus is currently on the company’s probiotic business and proprietary product Lactobacillus fermentum PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.

Bioxyne holds approximately 5% of the share capital of Mariposa Health Limited, a pharmaceutical development company with a focus on Congestive and Obstructive Pulmonary Disease (COPD).

The Bioxyne team has extensive skills and knowledge in identifying and commercialising life sciences, health and medical technologies. Bioxyne is actively pursuing new opportunities in the immune health sector that will enhance future value for its shareholders.

Bioxyne manufactures ans markets two products  itself. Progastrim for improved gut health and Protract for atopic dematitis.

The Bioxyne board, backed by a supportive shareholder base, is positioned to pursue new growth opportunities.

Board & Management

Anthony Ho

Non-Executive Chairman

George Cameron-Dow

Non-Executive Director

Patrick Ford

Non-Executive Director

Dr. Peter French

Chief Scientist